MGMT and neoplasm: Patients with glioma of subtype 1, which had a better survival outcome, exhibited lower pathological grades, smaller tumor volumes, and a higher proportion of cases with both MGMT promoter methylation and IDH mutation, consistent with previous research [11, 28, 40].